Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post-Marketing Study

Haemophilia. 2025 Aug 21. doi: 10.1111/hae.70099. Online ahead of print.

Authors

Pål André Holme¹, Lone Hvitfeldt Poulsen², Claudia Tueckmantel³, Monika Maas Enriquez³, María Teresa Alvarez Román⁴, Raimondo De Cristofaro⁵

Affiliations

¹ Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
² The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
³ Bayer AG, Wuppertal, Germany.
⁴ Hospital Universitario La Paz, Madrid, Spain.
⁵ Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy.

PMID: 40838268
DOI: 10.1111/hae.70099

Abstract

: This is a plain language summary of the results of a trial of damoctocog alfa pegol (BAY 94-9027, Jivi).

Keywords: damoctocog alfa pegol; haemophilia A; jivi; side effects.

© 2025 The Author(s). Haemophilia published by John Wiley & Sons Ltd.

Grants and funding

Bayer